Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis

E Pato, S Muñoz-Fernández, F Francisco… - Seminars in arthritis and …, 2011 - Elsevier
OBJECTIVES: To analyze the effectiveness of immunosuppressants and biological therapies
in autoimmune posterior uveitis, chronic anterior uveitis associated with juvenile idiopathic …

Increased risk of tuberculosis in patients with rheumatoid arthritis.

…, C Hernández-García, C Vadillo, E Pato… - The Journal of …, 2003 - jrheum.org
OBJECTIVE: To quantify the risk of tuberculosis (TB) in an unselected sample of patients with
rheumatoid arthritis (RA) compared to the risk in the general population. METHODS: The …

Efficacy of anti-IL6-receptor tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review

…, M Santos-Gómez, D Díaz-Valle, E Pato… - Ocular Immunology …, 2017 - Taylor & Francis
… Calvo-Río V, de la Hera D, Beltrán-Catalán E, et al. Tocilizumab in uveitis refractory to
other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol. …

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients

…, V Jovani, D Peiteado-Lopez, E Pato… - …, 2014 - academic.oup.com
Objective. The aim of this study was to assess the efficacy of anti-TNF-α therapy in refractory
uveitis due to Behçet’s disease (BD). Methods. We performed a multicentre study of 124 …

Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease: national multicenter study of 177 cases

…, V Jovaní, D Peiteado, E Pato… - Arthritis & …, 2019 - Wiley Online Library
Pato has received consulting fees and speaking fees from AbbVie, MSD, Novartis, and
Nordic Pharma (less than $10,000 each). Dr. Caracuel-Ruiz has received speaking fees from Eli …

Successful optimization of adalimumab therapy in refractory uveitis due to Behçet's disease

…, I Torre, D Díaz-Valle, E Pato, E Aurrecoechea… - Ophthalmology, 2018 - Elsevier
Purpose To assess efficacy, safety, and cost-effectiveness of adalimumab (ADA) therapy
optimization in a large series of patients with uveitis due to Behçet disease (BD) who achieved …

Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis.

…, IC Morado, P Macarrón, E Pato… - The Journal of …, 2000 - europepmc.org
Objective To study demographic and clinical variables associated with a longer delay in
disease modifying antirheumatic drug (DMARD) therapy initiation in a cohort of patients with …

Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis.

E Pato, A Bañares, JA Jover… - The Journal of …, 2000 - europepmc.org
Objective To investigate patients with formerly undiagnosed underlying spondyloarthropathy
(SpA) in a series of anterior uveitis (AU) cases and to describe the rheumatologic and …

Can calcium aluminates activate ternesite hydration?

M Montes, E Pato, PM Carmona-Quiroga… - Cement and Concrete …, 2018 - Elsevier
Aluminum hydroxide (AH 3 ) has recently been shown to be able to activate hydration in
ternesite, a phase found in some calcium sulfoaluminate (CSA) cements. This study explored …

Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice

…, Z Rosales, A Gomez, JR Lamas, E Pato… - Scandinavian journal …, 2016 - Taylor & Francis
Objectives: To assess and compare the long-term drug survival (time to drug discontinuation)
of biological agents (BA) in patients with rheumatoid arthritis (RA) in clinical practice. …